Monalizumab

Monalizumab (IPH2201) is an investigational agent whose form is not stated in the registry developed by AstraZeneca and MedImmune. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Participants will receive IV infusion of monalizumab as stated in arm description. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT05221840 (A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer) and NCT04590963 (Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer), in non-small-cell lung cancer and head and neck squamous cell carcinoma. The largest, NCT05221840, plans to enrol 1051 participants (actual) with primary completion expected 2026-09-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.